yorkshire cancer research Company Information
Company Number
01919823
Next Accounts
Dec 2025
Industry
Other human health activities
Shareholders
-
Group Structure
View All
Contact
Registered Address
unit a3 hornbeam square west, harrogate, north yorkshire, HG2 8PA
yorkshire cancer research Estimated Valuation
Pomanda estimates the enterprise value of YORKSHIRE CANCER RESEARCH at £31.8m based on a Turnover of £31.7m and 1x industry multiple (adjusted for size and gross margin).
yorkshire cancer research Estimated Valuation
Pomanda estimates the enterprise value of YORKSHIRE CANCER RESEARCH at £129.4m based on an EBITDA of £16.9m and a 7.67x industry multiple (adjusted for size and gross margin).
yorkshire cancer research Estimated Valuation
Pomanda estimates the enterprise value of YORKSHIRE CANCER RESEARCH at £280m based on Net Assets of £113.9m and 2.46x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Yorkshire Cancer Research Overview
Yorkshire Cancer Research is a live company located in north yorkshire, HG2 8PA with a Companies House number of 01919823. It operates in the other human health activities sector, SIC Code 86900. Founded in June 1985, it's largest shareholder is unknown. Yorkshire Cancer Research is a mature, large sized company, Pomanda has estimated its turnover at £31.7m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Yorkshire Cancer Research Health Check
Pomanda's financial health check has awarded Yorkshire Cancer Research a 5 rating. We use a traffic light system to show it exceeds the industry average on 8 measures and has 3 areas for improvement. Company Health Check FAQs
8 Strong
1 Regular
3 Weak
Size
annual sales of £31.7m, make it larger than the average company (£708.9k)
£31.7m - Yorkshire Cancer Research
£708.9k - Industry AVG
Growth
3 year (CAGR) sales growth of 16%, show it is growing at a faster rate (7.2%)
16% - Yorkshire Cancer Research
7.2% - Industry AVG
Production
with a gross margin of 38.5%, this company has a comparable cost of product (38.5%)
38.5% - Yorkshire Cancer Research
38.5% - Industry AVG
Profitability
an operating margin of 52.2% make it more profitable than the average company (5.1%)
52.2% - Yorkshire Cancer Research
5.1% - Industry AVG
Employees
with 102 employees, this is above the industry average (18)
102 - Yorkshire Cancer Research
18 - Industry AVG
Pay Structure
on an average salary of £40.1k, the company has a higher pay structure (£26.5k)
£40.1k - Yorkshire Cancer Research
£26.5k - Industry AVG
Efficiency
resulting in sales per employee of £311.1k, this is more efficient (£45.6k)
£311.1k - Yorkshire Cancer Research
£45.6k - Industry AVG
Debtor Days
it gets paid by customers after 39 days, this is later than average (20 days)
39 days - Yorkshire Cancer Research
20 days - Industry AVG
Creditor Days
its suppliers are paid after 4 days, this is quicker than average (18 days)
4 days - Yorkshire Cancer Research
18 days - Industry AVG
Stock Days
it holds stock equivalent to 0 days, this is less than average (13 days)
0 days - Yorkshire Cancer Research
13 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 176 weeks, this is more cash available to meet short term requirements (128 weeks)
176 weeks - Yorkshire Cancer Research
128 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 3.8%, this is a lower level of debt than the average (22%)
3.8% - Yorkshire Cancer Research
22% - Industry AVG
YORKSHIRE CANCER RESEARCH financials
Yorkshire Cancer Research's latest turnover from March 2024 is £31.7 million and the company has net assets of £113.9 million. According to their latest financial statements, Yorkshire Cancer Research has 102 employees and maintains cash reserves of £15.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 31,736,152 | 32,812,406 | 25,831,521 | 20,288,906 | 18,716,737 | 12,789,325 | 11,031,796 | 20,891,423 | 6,818,405 | 17,778,107 | 5,139,520 | 4,199,978 | 6,212,124 | 4,220,438 | 5,182,261 |
Other Income Or Grants | |||||||||||||||
Cost Of Sales | |||||||||||||||
Gross Profit | |||||||||||||||
Admin Expenses | |||||||||||||||
Operating Profit | |||||||||||||||
Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-Tax Profit | 13,115,032 | 16,778,601 | 15,014,867 | 12,469,419 | 5,629,211 | 4,437,218 | 4,779,998 | 15,754,424 | 1,281,028 | 13,522,705 | 59,657 | -2,038,228 | -2,114,191 | -2,146,253 | -3,079,834 |
Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Tax | 13,115,032 | 16,778,601 | 15,014,867 | 12,469,419 | 5,629,211 | 4,437,218 | 4,779,998 | 15,754,424 | 1,281,028 | 13,522,705 | 59,657 | -2,038,228 | -2,114,191 | -2,146,253 | -3,079,834 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Profit | 13,115,032 | 16,778,601 | 15,014,867 | 12,469,419 | 5,629,211 | 4,437,218 | 4,779,998 | 15,754,424 | 1,281,028 | 13,522,705 | 59,657 | -2,038,228 | -2,114,191 | -2,146,253 | -3,079,834 |
Employee Costs | 4,092,086 | 2,994,054 | 2,468,811 | 2,143,836 | 1,725,445 | 1,425,581 | 1,258,765 | 1,147,361 | 1,084,014 | 886,953 | 853,300 | 755,331 | 670,599 | 732,429 | 762,508 |
Number Of Employees | 102 | 73 | 61 | 52 | 41 | 37 | 34 | 32 | 30 | 28 | 21 | 19 | 19 | 22 | 23 |
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 2,828,413 | 985,538 | 226,519 | 176,900 | 150,891 | 87,715 | 92,523 | 93,562 | 125,033 | 240,761 | 155,735 | 148,765 | 168,272 | 169,554 | 155,616 |
Intangible Assets | 34,465 | 35,618 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 88,215,727 | 73,516,152 | 58,565,913 | 40,958,057 | 28,157,488 | 33,861,409 | 30,487,067 | 33,859,051 | 22,169,320 | 17,238,962 | 9,008,148 | 9,406,061 | 12,339,014 | 13,277,352 | 13,668,002 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 91,078,605 | 74,537,308 | 58,792,432 | 41,134,957 | 28,308,379 | 33,949,124 | 30,579,590 | 33,952,613 | 22,294,353 | 17,479,723 | 9,163,883 | 9,554,826 | 12,507,286 | 13,446,906 | 13,823,618 |
Stock & work in progress | 42,619 | 31,649 | 34,550 | 0 | 6,011 | 0 | 0 | 14,045 | 22,078 | 0 | 0 | 0 | 5,155 | 5,100 | 4,147 |
Trade Debtors | 3,435,607 | 584,889 | 626,353 | 425,261 | 2,883,073 | 3,028,678 | 1,476,796 | 4,215,646 | 382,071 | 1,627,340 | 182,172 | 569,608 | 802,110 | 823,889 | 2,674,329 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 8,634,233 | 9,638,511 | 8,174,461 | 5,981,098 | 6,808,557 | 2,008,604 | 1,682,759 | 708,005 | 730,725 | 338,525 | 123,915 | 157,001 | 179,721 | 116,513 | 159,725 |
Cash | 15,260,433 | 19,496,438 | 19,901,965 | 28,109,452 | 22,218,626 | 14,889,706 | 14,248,269 | 4,500,311 | 2,841,073 | 5,874,037 | 2,247,705 | 2,701,227 | 710,447 | 444,567 | 481,649 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 27,372,892 | 29,751,487 | 28,737,329 | 34,515,811 | 31,916,267 | 19,926,988 | 17,407,824 | 9,438,007 | 3,975,947 | 7,839,902 | 2,553,792 | 3,427,836 | 1,697,433 | 1,390,069 | 3,319,850 |
total assets | 118,451,497 | 104,288,795 | 87,529,761 | 75,650,768 | 60,224,646 | 53,876,112 | 47,987,414 | 43,390,620 | 26,270,300 | 25,319,625 | 11,717,675 | 12,982,662 | 14,204,719 | 14,836,975 | 17,143,468 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 246,546 | 529,559 | 314,272 | 69,892 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 202 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 4,259,909 | 2,929,226 | 3,164,080 | 6,544,334 | 3,657,526 | 2,883,275 | 1,461,225 | 1,230,745 | 1,186,416 | 1,037,369 | 1,255,976 | 2,676,610 | 2,604,993 | 931,924 | 1,591,685 |
total current liabilities | 4,506,657 | 3,458,987 | 3,478,554 | 6,614,428 | 3,657,728 | 2,883,477 | 1,461,427 | 1,230,947 | 1,186,618 | 1,037,571 | 1,256,178 | 2,676,812 | 2,605,195 | 931,924 | 1,591,685 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 54,928 | 28,328 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 0 | 54,928 | 28,328 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total liabilities | 4,506,657 | 3,458,987 | 3,478,554 | 6,614,428 | 3,657,728 | 2,938,405 | 1,489,755 | 1,230,947 | 1,186,618 | 1,037,571 | 1,256,178 | 2,676,812 | 2,605,195 | 931,924 | 1,591,685 |
net assets | 113,944,840 | 100,829,808 | 84,051,207 | 69,036,340 | 56,566,918 | 50,937,707 | 46,497,659 | 42,159,673 | 25,083,682 | 24,282,054 | 10,461,497 | 10,305,850 | 11,599,524 | 13,905,051 | 15,551,783 |
total shareholders funds | 113,944,840 | 100,829,808 | 84,051,207 | 69,036,340 | 56,566,918 | 50,937,707 | 46,497,659 | 42,159,673 | 25,083,682 | 24,282,054 | 10,461,497 | 10,305,850 | 11,599,524 | 13,905,051 | 15,551,783 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | |||||||||||||||
Depreciation | 271,986 | 77,001 | 88,321 | 54,894 | 29,667 | 27,683 | 20,328 | 37,622 | 47,344 | 48,152 | 31,206 | 28,905 | 0 | 29,932 | 29,090 |
Amortisation | 31,566 | 29,312 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock | 10,970 | -2,901 | 34,550 | -6,011 | 6,011 | 0 | -14,045 | -8,033 | 22,078 | 0 | 0 | -5,155 | 55 | 953 | 4,147 |
Debtors | 1,846,440 | 1,422,586 | 2,394,455 | -3,285,271 | 4,654,348 | 1,877,727 | -1,764,096 | 3,810,855 | -853,069 | 1,659,778 | -420,522 | -255,222 | 41,429 | -1,893,652 | 2,834,054 |
Creditors | -283,013 | 215,287 | 244,380 | 69,892 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 1,330,683 | -234,854 | -3,380,254 | 2,886,808 | 774,251 | 1,422,050 | 230,480 | 44,329 | 149,047 | -218,607 | -1,420,634 | 71,617 | 1,673,069 | -659,761 | 1,591,685 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | -54,928 | 26,600 | 28,328 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | |||||||||||||||
Investing Activities | |||||||||||||||
capital expenditure | 0 | 0 | 0 | 0 | 0 | -3,259,676 | 3,350,790 | -11,695,882 | -4,572,365 | -8,066,139 | 456,769 | 3,668,109 | 716,026 | 860,162 | 1,287,501 |
Change in Investments | 14,699,575 | 14,950,239 | 17,607,856 | 12,800,569 | -5,703,921 | 3,374,342 | -3,371,984 | 11,689,731 | 4,930,358 | 8,230,814 | -397,913 | -2,932,953 | -938,338 | -390,650 | 13,668,002 |
cash flow from investments | -14,699,575 | -14,950,239 | -17,607,856 | -12,800,569 | 5,703,921 | -6,634,018 | 6,722,774 | -23,385,613 | -9,502,723 | -16,296,953 | 854,682 | 6,601,062 | 1,654,364 | 1,250,812 | -12,380,501 |
Financing Activities | |||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 202 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||||||||||
interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from financing | 0 | 0 | 0 | 3 | 0 | 2,830 | -442,012 | 1,321,567 | -479,400 | 297,852 | 95,990 | 744,554 | -191,134 | 499,521 | 18,631,617 |
cash and cash equivalents | |||||||||||||||
cash | -4,236,005 | -405,527 | -8,207,487 | 5,890,826 | 7,328,920 | 641,437 | 9,747,958 | 1,659,238 | -3,032,964 | 3,626,332 | -453,522 | 1,990,780 | 265,880 | -37,082 | 481,649 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -4,236,005 | -405,527 | -8,207,487 | 5,890,826 | 7,328,920 | 641,437 | 9,747,958 | 1,659,238 | -3,032,964 | 3,626,332 | -453,522 | 1,990,780 | 265,880 | -37,082 | 481,649 |
yorkshire cancer research Credit Report and Business Information
Yorkshire Cancer Research Competitor Analysis
Perform a competitor analysis for yorkshire cancer research by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other large companies, companies in HG2 area or any other competitors across 12 key performance metrics.
yorkshire cancer research Ownership
YORKSHIRE CANCER RESEARCH group structure
Yorkshire Cancer Research has 2 subsidiary companies.
Ultimate parent company
YORKSHIRE CANCER RESEARCH
01919823
2 subsidiaries
yorkshire cancer research directors
Yorkshire Cancer Research currently has 16 directors. The longest serving directors include Mrs Sandra Dodson (Apr 2014) and Dr Yvette Oade (Apr 2014).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mrs Sandra Dodson | England | 71 years | Apr 2014 | - | Director |
Dr Yvette Oade | England | 65 years | Apr 2014 | - | Director |
Mr Robert Ndawula | United Kingdom | 50 years | Oct 2018 | - | Director |
Ms Elizabeth Richards | United Kingdom | 67 years | Nov 2018 | - | Director |
Mrs Clare Field | England | 57 years | Mar 2019 | - | Director |
Dr James Rice | England | 56 years | Jul 2020 | - | Director |
Mr Craig Bonnar | England | 51 years | Jan 2021 | - | Director |
Mr Samuel Jenner | England | 40 years | Jun 2022 | - | Director |
Mr Matthew Johnson | England | 57 years | Jun 2022 | - | Director |
Sir Robert Langlands | England | 72 years | Sep 2022 | - | Director |
P&L
March 2024turnover
31.7m
-3%
operating profit
16.6m
0%
gross margin
38.6%
+3.57%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
113.9m
+0.13%
total assets
118.5m
+0.14%
cash
15.3m
-0.22%
net assets
Total assets minus all liabilities
yorkshire cancer research company details
company number
01919823
Type
Private Ltd By Guarantee w/o Share Cap
industry
86900 - Other human health activities
incorporation date
June 1985
age
39
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
yorkshire cancer research campaign (December 1997)
accountant
-
auditor
RSM UK AUDIT LLP
address
unit a3 hornbeam square west, harrogate, north yorkshire, HG2 8PA
Bank
LLOYDS TSB BANK PLC
Legal Advisor
-
yorkshire cancer research Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to yorkshire cancer research.
yorkshire cancer research Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for YORKSHIRE CANCER RESEARCH. This can take several minutes, an email will notify you when this has completed.
yorkshire cancer research Companies House Filings - See Documents
date | description | view/download |
---|